Singapore Market Roundup, Singapore Market Roundup

Singapore Market Roundup

Thematic (Sector/Industry)

<ul>
<li>UOBKH lifts Valuetronics target price to $1.88 due to strong earnings outlook.</li>
<li>DBS's Tan keeps 'hold' on MINT amid wait for positive developments.</li>
<li>DBS keeps 'buy' on IHH Healthcare, raising target price to $3.39.</li>
</ul>


UOBKH lifts Valuetronics target price to $1.88 due to strong earnings outlook.
DBS's Tan keeps 'hold' on MINT amid wait for positive developments.
DBS keeps 'buy' on IHH Healthcare, raising target price to $3.39.


Singapore Market Roundup (29-May-2026): UOBKH raises Valuetronics target to $1.88 on strong

<ul><li>DBS rates Wee Hur Holdings as 'buy' with a target price of 90 cents.</li><li>PhillipCapital resumes coverage on iX Biopharma, setting a target price of $1.</li><li>New private hospital to have minimal effect on current healthcare providers: DBS</li></ul>

DBS rates Wee Hur Holdings as 'buy' with a target price of 90 cents.PhillipCapital resumes coverage on iX Biopharma, setting a target price of $1.New private hospital to have minimal effect on current healthcare providers: DBS

Singapore Market Roundup (10-Apr-2026): DBS rates Wee Hur Holdings a 'buy' at 90 cents target.

External broker reports(aggregated public sources), Topline Securities

Topline Securities

External broker reports(aggregated public sources)

Topline Securities is one of the fastest growing brokerage houses in Pakistan. It has strong equity brokerage, economic / equity research, mutual fund distribution, commodity trading and corporate finance & advisory functions. Content available is external broker reports authored by a third party outside the Smartkarma network and has been aggregated by an online aggregator through publicly available sources and is displayed by Smartkarma in this format for user's convenience and general informational purposes only. Content does not constitute investment or financial advice and Smartkarma makes no representation or warranty regarding its accuracy or contents. Original third party author retains all copyright and other proprietary rights in the content. Access or use of third party links not controlled by Smartkarma are at the user's own risk.

<ul><li>Pakistan market is expected to continue its uptrend in 2017 given tangible gains from China Pakistan Economic Corridor (CPEC) projects and rising domestic demand leading to higher economic growth prospects. This coupled with liquidity with local investors will likely set the stage for further gains in 2017, we believe.</li><li>Pakistan market currently trades at 2017F PE of 9.6x, which is at 23% and 29% discount to Morgan Stanley Composite Index (MSCI) Frontier Markets (FM) forward PE of 12.4x and MSCI Emerging Markets (EM) forward PE of 13.6x, respectively. We are of the view that Pakistan Market PE can potentially re-rate to 10x in 2017. This would be in line with the PE witnessed during high growth period of 2005-08 when Pakistan was part of EM index.</li><li>We expect benchmark KSE-100 Index to rise to 56,000 points by Dec 2017 generating 21% returns (inclusive of dividend). Our sample companies’ profit (representing 70% of KSE-100 index) is expected to grow by 23% in 2017, compared to increase of 1% in 2016, due to 1) re-bound in oil prices and higher oil production, 2) bottoming out of interest rates, 3) higher sales of oil, fertilizer and autos and 4) increased investment in energy sector.</li><li>Resultantly, we expect market capitalization of Pakistan to cross US$100bn in 2017 (30% of GDP) vs. US$89bn now.</li><li>Among other events that can potentially impact market movement is transition to MSCI EM in May 2017, which will keep optimism high. Further, local political issues, global sell-off and delays in implementation of CPEC projects can affect local bourse in 2017, we believe.</li><li>During 2016 YTD, the KSE-100 Index is up 41% compared to relatively flat performance in 2015. This is despite foreign selling of US$267mn during the year, thanks to local liquidity where local mutual funds bought US$264mn and Non-Banking Financial Corporations (NBFC) bought US$215mn whereas Companies and Banks sold total of US$221mn. Pakistan market performance in 2016 remained exceptional compared to regional markets where MSCI FM is down 2% while MSCI EM increased 10% in 2016 YTD.</li><li>We maintain ‘overweight’ stance on Cements, Consumers/Autos, Oil &amp; Gas Marketing and Steel sectors. We expect these sectors to be prime beneficiaries of rising domestic demand and expansion activities led by CPEC. We are of the view that Banks/Insurance will continue to benefit from increased economic activity.</li><li>Our top picks for 2017, which are expected to generate above average returns, are: Habib Bank (HBL), Lucky Cement (LUCK), Pakistan State Oil (PSO), DG Khan Cement (DGKC), Sui North Gas Pipelines (SNGP), Pak Suzuki Motors (PSMC), Pak Elektron (PAEL) and Adamjee Insurance (AICL).</li></ul>

Pakistan market is expected to continue its uptrend in 2017 given tangible gains from China Pakistan Economic Corridor (CPEC) projects and rising domestic demand leading to higher economic growth prospects. This coupled with liquidity with local investors will likely set the stage for further gains in 2017, we believe.Pakistan market currently trades at 2017F PE of 9.6x, which is at 23% and 29% discount to Morgan Stanley Composite Index (MSCI) Frontier Markets (FM) forward PE of 12.4x and MSCI Emerging Markets (EM) forward PE of 13.6x, respectively. We are of the view that Pakistan Market PE can potentially re-rate to 10x in 2017. This would be in line with the PE witnessed during high growth period of 2005-08 when Pakistan was part of EM index.We expect benchmark KSE-100 Index to rise to 56,000 points by Dec 2017 generating 21% returns (inclusive of dividend). Our sample companies’ profit (representing 70% of KSE-100 index) is expected to grow by 23% in 2017, compared to increase of 1% in 2016, due to 1) re-bound in oil prices and higher oil production, 2) bottoming out of interest rates, 3) higher sales of oil, fertilizer and autos and 4) increased investment in energy sector.Resultantly, we expect market capitalization of Pakistan to cross US$100bn in 2017 (30% of GDP) vs. US$89bn now.Among other events that can potentially impact market movement is transition to MSCI EM in May 2017, which will keep optimism high. Further, local political issues, global sell-off and delays in implementation of CPEC projects can affect local bourse in 2017, we believe.During 2016 YTD, the KSE-100 Index is up 41% compared to relatively flat performance in 2015. This is despite foreign selling of US$267mn during the year, thanks to local liquidity where local mutual funds bought US$264mn and Non-Banking Financial Corporations (NBFC) bought US$215mn whereas Companies and Banks sold total of US$221mn. Pakistan market performance in 2016 remained exceptional compared to regional markets where MSCI FM is down 2% while MSCI EM increased 10% in 2016 YTD.We maintain ‘overweight’ stance on Cements, Consumers/Autos, Oil &amp; Gas Marketing and Steel sectors. We expect these sectors to be prime beneficiaries of rising domestic demand and expansion activities led by CPEC. We are of the view that Banks/Insurance will continue to benefit from increased economic activity.Our top picks for 2017, which are expected to generate above average returns, are: Habib Bank (HBL), Lucky Cement (LUCK), Pakistan State Oil (PSO), DG Khan Cement (DGKC), Sui North Gas Pipelines (SNGP), Pak Suzuki Motors (PSMC), Pak Elektron (PAEL) and Adamjee Insurance (AICL).

SGX Market Strategist, Equity & Fixed Income, Singapore Exchange Ltd (SGX)

Geoff Howie

SGX Market Strategist, Equity & Fixed Income

Asia’s leading multi-asset exchange

Singapore Exchange Ltd (SGX)

Singapore Exchange is Asia’s leading and trusted market infrastructure, facilitating the exchange of capital and ideas to create value for people, businesses and economies. As a multi-asset exchange operating equity, fixed income and derivatives markets to the highest regulatory standards, SGX is a vertically integrated business that provides listing, trading, clearing, settlement, depository and data services.

With about 40% of listed companies and over 80% of listed bonds originating outside of Singapore as well as established linkages across the region and in Europe, SGX is Asia’s most international and connected exchange. Offering a full suite of derivatives products across Asian equity indices, commodities and currencies, SGX is the world’s most liquid international market for the benchmark equity indices of China, India, Japan and ASEAN.

As Asia’s pioneering central counterparty, SGX is globally recognised for its risk management and clearing capabilities, and was one of the first globally to adopt the Principles for Financial Market Infrastructure.

Headquartered in AAA-rated Singapore, SGX has over 800 employees including offices in Beijing, Chicago, Hong Kong, London, New York, Mumbai, San Francisco, Shanghai and Tokyo.

Equity Bottom-Up

<figure class="editor-figure mceNonEditable"><img src="https://api2.sgx.com/sites/default/files/2021-12/IHH-CEO.png" class="editor-image img-responsive"></figure>
<div class="content-caption">IHH - CEO</div>

While growing up, Dr Kelvin Loh had dreamed of becoming an engineer, building and fixing machines. However, reaching a crossroads decades later, he pivoted to pursue medicine as a career. “Healthcare wasn’t the path I had always wanted to take. Truth be told, I was on my way to become a computer engineer, as I had received an overseas scholarship to study that discipline in the UK,” recalled the Chief Executive Officer of IHH Healthcare Bhd, which is dual-listed on SGX and Bursa Malaysia. “But I thought about it and decided that working to improve computer systems wasn’t really what I wanted to devote my life to - I wanted to help people.” As it turned out, Loh would fulfil these two aspirations - the desire to help patients and the passion to improve systems - in his career journey spanning more than two decades in the healthcare industry. Loh holds a Bachelor of Medicine, Bachelor of Surgery and a Master of Business Administration from the National University of Singapore. He spent the early years of his career as a general physician, until a growing passion to improve healthcare systems launched him on the management track in Singapore’s public healthcare sector. During his days as a junior doctor, Loh had been taken aback by the delays and wastage in the healthcare system. “From both a patient’s and doctor’s perspective, it was something incredibly frustrating, and I resolved to bring systemic change to the medical world.” “For that reason, I moved out of medical practice and started a healthcare administration job. It was hard to explain to people why I spent five years studying to become a doctor only to decide not to be one. But to me, something about finding ways to fix processes was just so inspiring,” he recounted. The 48-year-old subsequently spent a decade serving in areas such as clinical services development, hospital planning and hospital operations.&nbsp; In 2008, he joined IHH Healthcare, and held various senior management roles between then and 2017, before taking over as CEO of the Singapore Operations Division, now known as IHH Healthcare Singapore. In that role, he was responsible for the Group’s four multi-specialty tertiary hospitals - Mount Elizabeth Orchard, Mount Elizabeth Novena, Gleneagles, and Parkway East.&nbsp; In 2017, Loh moved to helm Columbia Asia Group, overseeing its 28 hospitals across India, Malaysia, Vietnam, and Indonesia. He rejoined IHH in July 2019 as CEO designate, assuming the position of Managing Director and Group CEO in January 2020.&nbsp; True North “Many would consider it unfortunate I took the reins of IHH right before COVID-19 struck. It was a tough and challenging time, but also an opportunity to reset things, and look at where we’ve done well and where we’ve not, so we can improve,” Loh noted. “One lesson learnt is that even in the best efforts of mapping out trends and doing strategic planning, one cannot fully predict the future. Nothing could have exemplified this better than the pandemic. Hence, it’s important to build adaptability in the organisation, which in turn provides resilience.” To achieve this, organisations must have a True North, a purpose that enables right decisions to be taken when unexpected situations arise, Loh added.&nbsp; “For us, that comes from our vision to be the world’s most trusted healthcare services network. COVID-19 tested our resolve - but it was exactly that focus on making sure patients and staff can keep trusting us in the hardest of times, that we’ve been able to keep them safe and look after their livelihoods. That has enabled us to survive and recover strongly from the crisis.” Listed on both Bursa Malaysia and SGX since July 2012, IHH Healthcare offers its patients a full spectrum of integrated healthcare services, ranging from clinics and hospitals, to highly specialised care and a wide range of acute medical services. The Group employs over 65,000 people across 80 hospitals in 10 countries. Its geographical footprint spans Malaysia, Singapore, Turkey, and India, as well as Greater China, including Hong Kong. Its portfolio of trusted healthcare brands include Pantai, Gleneagles and Prince Court in IHH Malaysia; Mount Elizabeth, Gleneagles, and Parkway in IHH Singapore; Gleneagles and ParkwayHealth in IHH Greater China; Fortis, Global and Continental in IHH India, as well as Acibadem in Turkey.&nbsp; “When I first took over, IHH was at a point where it needed to pivot for the next growth phase, and I set a bold target to double ROE over five years,” Loh noted, referring to return on equity, a key industry metric. “One of my priorities was to come up with a Refreshed Strategy, which we unveiled in February 2020. This enabled us to respond swiftly to evolving patient trends, such as digitalisation and telemedicine, even before the pandemic, which allowed us to build on the trust our stakeholders have in us.” Building Resilience COVID-19, however, intensified the challenge of building resilience in the Group’s operations, which were most impacted at the height of the pandemic in April and May 2020 following national lockdowns. “Despite this, we took on COVID-19 support services and navigated the pandemic with strict cost controls. As a result, we’ve reported a sustained recovery since June 2020,” Loh said. “As a healthcare provider, our immediate and continuing priority lies in supporting governments across the world in their fight against COVID-19. This includes providing COVID-19 lab testing, allocating beds to treat COVID-19 patients, and running vaccination centres. In fact, our laboratories have already conducted more than 8 million COVID-19-related tests since 2020,” he added. In retrospect, Loh is gratified by how his team pulled together to achieve their goals despite the hurdles. “Not only did we survive, we thrived, with our target to increase returns bearing fruit, and financial targets more than met.&nbsp; More importantly, we as healthcare providers made a real difference by stepping up and working hand-in-glove with governments.” In the long run, he believes hospitals will continue to transform the face of healthcare, and meet patient demand for faster, affordable, and more convenient services. “The future of hospital care is one that will be both high-tech and high-touch,” he added. Disruption from the pandemic has already generated the imperative to innovate and digitise. Despite being at the forefront of innovation, COVID-19 has accelerated IHH’s digital healthcare journey.&nbsp; “We see increased investments in digitalisation and innovation as a host of new technologies are integrated into care delivery, such as telemedicine, artificial intelligence, genomics and precision medicine.” Driving Value Additionally, with the escalating cost of healthcare a concern in many countries, there’s increased patient focus on value, price transparency and accountability, Loh said. “At IHH, we’re already leveraging cutting-edge technology - in 2018, we launched an AI-powered, predictive hospital bill estimation system to dynamically generate personalised, more accurate hospital bill estimates,” he added. “This has empowered patients to make better-informed decisions on available treatment options and provided greater peace of mind and transparency. As a Group, we’re always committed to enhancing price transparency of our hospital charges.” Apart from the Group’s day-to-day operations, Loh is also focused on Environmental, Social and Governance (ESG) targets. “At IHH, we recognise our responsibility to the global community in contributing towards a healthy and sustainable future. We’re passionate about building a business that’s firmly anchored on making healthcare better for every patient,” he said. A clear example of this is IHH’s Value-Driven Outcomes (VDO) global initiative, which identifies and predicts outcomes and costs of its care, using data to drive more value for patients. This programme has been rolled out for several common high-volume and high-impact medical procedures across five markets. “There’s much to be done in terms of battling climate change, and we’ll continue to take major steps in this sustainability journey, which includes setting targets on our carbon footprint, emissions and waste management.” Given the intense and demanding nature of his role, there is much that occupies Loh, even into the wee hours. “Because healthcare is a traditional, hierarchical service, I worry that we’re too slow to evolve and too slow to respond to patients, who will no longer just be patient. They are, today, also consumers, consumers who want value, convenience and empowerment. Nonetheless, Loh makes it a point to carve out some downtime, which is spent exercising with his 10-year-old son and cooking for the family.&nbsp; “My advice to my son and staff is this: Do the best in whatever you choose to do at any point in time. See failure as a way of not doing something well, so that the next time, you can find a way to do it better,” he noted. “When you have exhausted all the ways of not succeeding, you can then discover the way to succeed.” IHH Healthcare Bhd IHH is a leading international healthcare operator offering our patients a full spectrum of integrated healthcare services from clinics to hospitals to highly specialised care and a wide range of acute medical services. Our wide geographical footprint extends across our home markets of Malaysia, Singapore, Turkey, and India, as well as our key growth market of Greater China, including Hong Kong. Our portfolio of trusted premium healthcare brands includes Pantai, Gleneagles and Prince Court in IHH Malaysia; Mount Elizabeth, Gleneagles, and Parkway in IHH Singapore; Gleneagles and ParkwayHealth in IHH Greater China; Fortis, Global and Continental in IHH India; and Acibadem in Turkey. We employ over 65,000 people across 80 hospitals in 10 countries, with a vision of becoming the world’s most trusted healthcare services network. The company website is: <a href="http://www.ihhhealthcare.com." target="_blank" rel="noopener">www.ihhhealthcare.com</a> Click&nbsp;<a href="https://www.sgx.com/securities/equities/Q0F" target="_blank" rel="noopener">here&nbsp;</a>for the company's StockFacts page. For the second quarter ended 30 June 2021 financial results, click&nbsp;<a href="https://links.sgx.com/1.0.0/corporate-announcements/2XWRDXSUQNBJ3MMN/681488_IHH%20Q2%202021%20Press%20Release%2026.08.2021.pdf" target="_blank" rel="noopener">here</a>. &nbsp;
About&nbsp;kopi-C: the Company brew
Text: Jennifer Tan-Stanisic Photo: Company file kopi-C&nbsp;is a regular column on the SGX Research website that features C-level executives of leading companies listed on Singapore Exchange. These interviews are profiles of senior management aimed at helping investors better understand the individuals who run these corporations. For previous editions of&nbsp;kopi-C: the Company brew,&nbsp;please click&nbsp;<a href="https://www.sgx.com/research-education/market-dialogues" target="_blank" rel="noopener">here</a>. &nbsp; For more information, or if you would like your senior executives to be featured on SGX Market Dialogues, please send suggestions to&nbsp;<a href="https://www.sgx.com/jennifer.t@sgx.com" target="_blank" rel="noopener">jennifer.t@sgx.com</a>.


IHH - CEO

While growing up, Dr Kelvin Loh had dreamed of becoming an engineer, building and fixing machines. However, reaching a crossroads decades later, he pivoted to pursue medicine as a career.  “Healthcare wasn’t the path I had always wanted to take. Truth be told, I was on my way to become a computer engineer, as I had received an overseas scholarship to study that discipline in the UK,” recalled the Chief Executive Officer of IHH Healthcare Bhd, which is dual-listed on SGX and Bursa Malaysia.  “But I thought about it and decided that working to improve computer systems wasn’t really what I wanted to devote my life to - I wanted to help people.”  As it turned out, Loh would fulfil these two aspirations - the desire to help patients and the passion to improve systems - in his career journey spanning more than two decades in the healthcare industry.  Loh holds a Bachelor of Medicine, Bachelor of Surgery and a Master of Business Administration from the National University of Singapore. He spent the early years of his career as a general physician, until a growing passion to improve healthcare systems launched him on the management track in Singapore’s public healthcare sector.  During his days as a junior doctor, Loh had been taken aback by the delays and wastage in the healthcare system. “From both a patient’s and doctor’s perspective, it was something incredibly frustrating, and I resolved to bring systemic change to the medical world.”  “For that reason, I moved out of medical practice and started a healthcare administration job. It was hard to explain to people why I spent five years studying to become a doctor only to decide not to be one. But to me, something about finding ways to fix processes was just so inspiring,” he recounted.  The 48-year-old subsequently spent a decade serving in areas such as clinical services development, hospital planning and hospital operations.&nbsp;  In 2008, he joined IHH Healthcare, and held various senior management roles between then and 2017, before taking over as CEO of the Singapore Operations Division, now known as IHH Healthcare Singapore. In that role, he was responsible for the Group’s four multi-specialty tertiary hospitals - Mount Elizabeth Orchard, Mount Elizabeth Novena, Gleneagles, and Parkway East.&nbsp;  In 2017, Loh moved to helm Columbia Asia Group, overseeing its 28 hospitals across India, Malaysia, Vietnam, and Indonesia. He rejoined IHH in July 2019 as CEO designate, assuming the position of Managing Director and Group CEO in January 2020.&nbsp;  True North  “Many would consider it unfortunate I took the reins of IHH right before COVID-19 struck. It was a tough and challenging time, but also an opportunity to reset things, and look at where we’ve done well and where we’ve not, so we can improve,” Loh noted.  “One lesson learnt is that even in the best efforts of mapping out trends and doing strategic planning, one cannot fully predict the future. Nothing could have exemplified this better than the pandemic. Hence, it’s important to build adaptability in the organisation, which in turn provides resilience.”  To achieve this, organisations must have a True North, a purpose that enables right decisions to be taken when unexpected situations arise, Loh added.&nbsp;  “For us, that comes from our vision to be the world’s most trusted healthcare services network. COVID-19 tested our resolve - but it was exactly that focus on making sure patients and staff can keep trusting us in the hardest of times, that we’ve been able to keep them safe and look after their livelihoods. That has enabled us to survive and recover strongly from the crisis.”  Listed on both Bursa Malaysia and SGX since July 2012, IHH Healthcare offers its patients a full spectrum of integrated healthcare services, ranging from clinics and hospitals, to highly specialised care and a wide range of acute medical services. The Group employs over 65,000 people across 80 hospitals in 10 countries.  Its geographical footprint spans Malaysia, Singapore, Turkey, and India, as well as Greater China, including Hong Kong. Its portfolio of trusted healthcare brands include Pantai, Gleneagles and Prince Court in IHH Malaysia; Mount Elizabeth, Gleneagles, and Parkway in IHH Singapore; Gleneagles and ParkwayHealth in IHH Greater China; Fortis, Global and Continental in IHH India, as well as Acibadem in Turkey.&nbsp;  “When I first took over, IHH was at a point where it needed to pivot for the next growth phase, and I set a bold target to double ROE over five years,” Loh noted, referring to return on equity, a key industry metric.  “One of my priorities was to come up with a Refreshed Strategy, which we unveiled in February 2020. This enabled us to respond swiftly to evolving patient trends, such as digitalisation and telemedicine, even before the pandemic, which allowed us to build on the trust our stakeholders have in us.”  Building Resilience  COVID-19, however, intensified the challenge of building resilience in the Group’s operations, which were most impacted at the height of the pandemic in April and May 2020 following national lockdowns.  “Despite this, we took on COVID-19 support services and navigated the pandemic with strict cost controls. As a result, we’ve reported a sustained recovery since June 2020,” Loh said.  “As a healthcare provider, our immediate and continuing priority lies in supporting governments across the world in their fight against COVID-19. This includes providing COVID-19 lab testing, allocating beds to treat COVID-19 patients, and running vaccination centres. In fact, our laboratories have already conducted more than 8 million COVID-19-related tests since 2020,” he added.  In retrospect, Loh is gratified by how his team pulled together to achieve their goals despite the hurdles. “Not only did we survive, we thrived, with our target to increase returns bearing fruit, and financial targets more than met.&nbsp; More importantly, we as healthcare providers made a real difference by stepping up and working hand-in-glove with governments.”  In the long run, he believes hospitals will continue to transform the face of healthcare, and meet patient demand for faster, affordable, and more convenient services. “The future of hospital care is one that will be both high-tech and high-touch,” he added.  Disruption from the pandemic has already generated the imperative to innovate and digitise. Despite being at the forefront of innovation, COVID-19 has accelerated IHH’s digital healthcare journey.&nbsp;  “We see increased investments in digitalisation and innovation as a host of new technologies are integrated into care delivery, such as telemedicine, artificial intelligence, genomics and precision medicine.”  Driving Value  Additionally, with the escalating cost of healthcare a concern in many countries, there’s increased patient focus on value, price transparency and accountability, Loh said.  “At IHH, we’re already leveraging cutting-edge technology - in 2018, we launched an AI-powered, predictive hospital bill estimation system to dynamically generate personalised, more accurate hospital bill estimates,” he added.  “This has empowered patients to make better-informed decisions on available treatment options and provided greater peace of mind and transparency. As a Group, we’re always committed to enhancing price transparency of our hospital charges.”  Apart from the Group’s day-to-day operations, Loh is also focused on Environmental, Social and Governance (ESG) targets.  “At IHH, we recognise our responsibility to the global community in contributing towards a healthy and sustainable future. We’re passionate about building a business that’s firmly anchored on making healthcare better for every patient,” he said.  A clear example of this is IHH’s Value-Driven Outcomes (VDO) global initiative, which identifies and predicts outcomes and costs of its care, using data to drive more value for patients. This programme has been rolled out for several common high-volume and high-impact medical procedures across five markets.  “There’s much to be done in terms of battling climate change, and we’ll continue to take major steps in this sustainability journey, which includes setting targets on our carbon footprint, emissions and waste management.”  Given the intense and demanding nature of his role, there is much that occupies Loh, even into the wee hours. “Because healthcare is a traditional, hierarchical service, I worry that we’re too slow to evolve and too slow to respond to patients, who will no longer just be patient. They are, today, also consumers, consumers who want value, convenience and empowerment.  Nonetheless, Loh makes it a point to carve out some downtime, which is spent exercising with his 10-year-old son and cooking for the family.&nbsp;  “My advice to my son and staff is this: Do the best in whatever you choose to do at any point in time. See failure as a way of not doing something well, so that the next time, you can find a way to do it better,” he noted.  “When you have exhausted all the ways of not succeeding, you can then discover the way to succeed.”   IHH Healthcare Bhd  IHH is a leading international healthcare operator offering our patients a full spectrum of integrated healthcare services from clinics to hospitals to highly specialised care and a wide range of acute medical services. Our wide geographical footprint extends across our home markets of Malaysia, Singapore, Turkey, and India, as well as our key growth market of Greater China, including Hong Kong. Our portfolio of trusted premium healthcare brands includes Pantai, Gleneagles and Prince Court in IHH Malaysia; Mount Elizabeth, Gleneagles, and Parkway in IHH Singapore; Gleneagles and ParkwayHealth in IHH Greater China; Fortis, Global and Continental in IHH India; and Acibadem in Turkey. We employ over 65,000 people across 80 hospitals in 10 countries, with a vision of becoming the world’s most trusted healthcare services network.  The company website is: www.ihhhealthcare.com  Click&nbsp;here&nbsp;for the company's StockFacts page.  For the second quarter ended 30 June 2021 financial results, click&nbsp;here.  &nbsp;
About&nbsp;kopi-C: the Company brew
Text: Jennifer Tan-Stanisic Photo: Company file  kopi-C&nbsp;is a regular column on the SGX Research website that features C-level executives of leading companies listed on Singapore Exchange. These interviews are profiles of senior management aimed at helping investors better understand the individuals who run these corporations.  For previous editions of&nbsp;kopi-C: the Company brew,&nbsp;please click&nbsp;here. &nbsp;  For more information, or if you would like your senior executives to be featured on SGX Market Dialogues, please send suggestions to&nbsp;jennifer.t@sgx.com.

IHH Healthcare Carves Out High-Tech, High-Touch Future

10 in 10 with IHH Healthcare - A Global Healthcare Network

Malaysia

IHH Healthcare Bhd provides healthcare services. The Company operates hospitals as well as medical centers, clinics and ancillary healthcare businesses across multiple countries, including Singapore, Malaysia, Turkey, The Peoples Republic of China, India, Hong Kong,  Macedonia, the Netherlands and Brunei.

Price Gauge
52-week Range	0.00 - 0.00
Market Cap (USDm)	0.00
P/E	0.00
Dividend (Yield)	0.00

IHH Healthcare (IHH MK)

Singapore Market Roundup (29-May-2026): UOBKH raises Valuetronics target to $1.88 on strong

UOBKH raises Valuetronics target price to $1.88 due to strong earnings. DBS's Tan maintains 'hold' on MINT while awaiting positive developments.

Singapore Market Roundup

Singapore Market Roundup (10-Apr-2026): DBS rates Wee Hur Holdings a 'buy' at 90 cents target.

DBS rates Wee Hur Holdings as 'buy' with a 90 cents target price. PhillipCapital resumes iX Biopharma coverage with a $1 target. New hospital won't...

Singapore Market Roundup

Pakistan Market Outlook 2017

Pakistan market is expected to continue its uptrend in 2017 given tangible gains from China Pakistan Economic Corridor (CPEC) projects and rising...

Topline Securities

IHH Healthcare Carves Out High-Tech, High-Touch Future

While growing up, Dr Kelvin Loh had dreamed of becoming an engineer, building and fixing machines. However, reaching a crossroads decades later,...

Singapore Exchange Ltd (SGX)

10 in 10 with IHH Healthcare - A Global Healthcare Network

Singapore Exchange Ltd (SGX)

Price Gauge

52-week Range

Market Cap (USDm)

P/E

Dividend (Yield)